IRVINE, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) — MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Navigation System will be on display at the Society for Neuro-Oncology (SNO) and the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) Joint Conference on Therapeutic Delivery to the CNS – November 15th and 16th, 2017, in San Francisco, CA. Attendees are invited to visit the MRI Interventions exhibit to learn about the use of the ClearPoint Neuro Navigation System for real-time MRI guided imaging and navigation during Convection Enhanced Delivery (CED) to the brain.
MRI Interventions is involved with six pre-clinical and clinical stage biopharmaceutical companies and their investigators to create a conventional platform for direct delivery of novel therapeutics to the brain utilizing the ClearPoint Neuro Navigation System. Investigators using the ClearPoint System and the SmartFlow® Ventricular Cannula to accommodate fragile cells, genes, proteins and small molecule therapeutics for interstitial infusion, will be speaking at this conference.
“We believe real-time, intra-operative MRI imaging with ClearPoint is becoming the standard for these drug delivery trials,” said Joe Burnett, President and CEO of MRI Interventions, Inc. “Use of the ClearPoint System enables precise targeting, trajectory planning, catheter placement and delivery of compounds to deep targets in the brain with real-time MRI visualization, all of which are critical to the success of these trials. We are pleased to see the use of our products in such a variety of initiatives, and look forward to exploring partnerships to expand into additional trials as well.”
About MRI Interventions, Inc.
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, both of which have been filed with the Securities and Exchange Commission.
MRI Interventions, Inc.
Matt Kreps, Darrow Associates Investor Relations